Article thumbnail

Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review

By Eric W Schneider and Mark W Johnson

Abstract

With the dissemination of optical coherence tomography over the past two decades, the role of persistent vitreomacular adhesion (VMA) in the development of numerous macular pathologies – including idiopathic macular hole, vitreomacular traction syndrome, cystoid and diabetic macular edema, neovascularization in diabetic retinopathy and retinal vein occlusion, exudative age-related macular degeneration, and myopic traction maculopathy – has been established. While invasive vitreoretinal procedures have long been utilized to address complications related to these disorders, such an approach is hampered by incomplete vitreoretinal separation and vitreous removal, surgical complications, and high costs. In light of such limitations, investigators have increasingly looked to nonsurgical means for the treatment of persistent pathologic VMA. Chief among these alternative measures is the intravitreal application of pharmacologic agents for the induction of vitreous liquefaction and/or vitreoretinal separation, an approach termed pharmacologic vitreolysis. This article aims to review the available evidence regarding the use of pharmacologic agents in the treatment of VMA-related pathology. In addition, a discussion of vitreous molecular organization and principles of physiologic posterior vitreous detachment is provided to allow for a consideration of vitreolytic agent mode of action and molecular targets

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3162296
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A method for induction of posterior vitreous detachment during vitrectomy.
  2. a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase.
  3. A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery.
  4. A new approach to stage 3 macular holes.
  5. (1998). A new model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci.
  6. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet.
  7. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy.
  8. A single injection of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (sVMA): results
  9. (1966). Acute posterior vitreous detachment and its retinal complications. Acta Ophthalmol.
  10. (1978). Affinity of fibronectin to collagens of different genetic types and to fibrinogen. J Exp Med.
  11. (2003). Age-dependent changes in the basal retinovitreous adhesion. Invest Ophthalmol Vis Sci.
  12. (1987). Age-related changes in human vitreous structure. Graefes Arch Clin Exp Ophthalmol.
  13. (1991). Age-related differences in the human vitreoretinal interface. Arch Ophthalmol.
  14. (2003). Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest Ophthalmol Vis Sci.
  15. and 25-gauge vitreous cutters: performance and characteristics evaluation.
  16. (2004). Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol.
  17. Anticipation for enzymatic vitreolysis.
  18. Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy.
  19. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery.
  20. Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial.
  21. Bacterial collagenase. Proposed adjunct to vitrectomy with membranectomy.
  22. (2005). Biochemical characterization of the chondroitinase ABC I active site. Biochem J.
  23. Chemical analysis of bovine and porcine vitreous humors: correlation of normal values with serum chemical values and changes with time and temperature.
  24. (1994). Chondroitinase-mediated disinsertion of the primate vitreous body [abstract]. Invest Ophthalmol Vis Sci (Suppl).
  25. (1996). Cleavage of structural components of mammalian vitreous by endogenous matrix metalloproteinase-2. Curr Eye Res.
  26. (2008). Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci.
  27. (1998). Comparative study of incomplete posterior vitreous detachment as a risk factor for proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol.
  28. (2005). Determine the safety and efficacy of Vitreosolve® administered intravitreally to induce a complete posterior vitreous detachment (PVD) in non proliferative diabetic retinopathy human subjects Invest Ophthalmol Vis Sci (Suppl).
  29. Effect of intravitreal hyaluronidase on the clearance of tritiated water from the vitreous to the choroid.
  30. (2009). Effect of intravitreal plasmin on vitreous removal through a 25-gauge cutting system in the rabbit in vivo. Graefes Arch Clin Exp Ophthalmol.
  31. Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.
  32. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res.
  33. (1999). Effects of hyaluronan lyase, hyaluronidase, and chondroitin ABC lyase on mammalian vitreous gel. Invest Ophthalmol Vis Sci.
  34. (2006). Effects of intravitreal dispase on vitreoretinal interface in rabbits. Curr Eye Res.
  35. (1987). Effects of visible-light irradiation on vitreous structure in the presence of a photosensitizer. Exp Eye Res.
  36. Efficacy and safety of enzymatic posterior vitreous detachment by intravitreal injection of hyaluronidase.
  37. Efficacy of autologous plasmin for idiopathic macular hole surgery.
  38. (2007). Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study. Graefes Arch Clin Exp Ophthalmol.
  39. (2000). Elevated levels of proteolytic enzymes in the aging human vitreous. Invest Ophthalmol Vis Sci.
  40. (1990). Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol.
  41. (2008). Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator. Eye (Lond).
  42. Enzymatic vitreous disruption.
  43. Enzymatic vitreous surgery.
  44. Enzymatic-assisted vitrectomy.
  45. (1984). Enzymatically induced posterior vitreous detachment [abstract]. Invest Ophthalmol Vis Sci (Suppl).
  46. (2004). Enzyme-assisted vitrectomy in enucleated pig eyes: a comparison of hyaluronidase, chondroitinase, and plasmin. Curr Eye Res.
  47. Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies.
  48. Enzyme-assisted vitrectomy with bacterial collagenase. Time course and toxicity studies.
  49. (2005). Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction.
  50. Experimental model for proliferative vitreoretinopathy by intravitreal dispase: limited by zonulolysis and cataract.
  51. Experimental occlusion of retinal and ciliary vessels in owl monkeys. I. Technique and clinical observations of selective embolism of the central retinal artery system. Exp Eye Res.
  52. (1985). Experimental vitreous syneresis. Arch Ophthalmol.
  53. Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate human neutrophil degranulation.
  54. (1986). Gas vitrectomy in a primate model. Graefes Arch Clin Exp Ophthalmol.
  55. (1984). Gas-mediated vitreous compression: an experimental alternative to mechanized vitrectomy. Graefes Arch Clin Exp Ophthalmol.
  56. (1998). Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett.
  57. Iatrogenic retinal breaks in 25-gauge macular surgery.
  58. (1987). Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci.
  59. Immunolocalization of integrins in the human retina.
  60. (2000). Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res.
  61. (2006). Induction of posterior vitreous separation using LASIK suction ring may have a potential role in the management of diabetic macular edema. Med Hypotheses.
  62. Induction of vitreolysis and vitreous detachment with hyaluronidase and perfluoropropane gas.
  63. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides.
  64. Integrins: versatility, modulation, and signaling in cell adhesion.
  65. Intrasurgical plasmin enzyme in diabetic macular edema.
  66. (2003). Intravitreal injection of dispase causes retinal hemorrhages in rabbit and human eyes. Curr Eye Res.
  67. (2000). Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina.
  68. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial).
  69. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous.
  70. Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion.
  71. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation.
  72. Is pharmacologic vitreolysis brewing?
  73. (1987). Is your vitreous really necessary? The role of the vitreous in the eye with particular reference to retinal attachment, detachment and the mode of action of vitreous substitutes. Eye (Lond).
  74. (1989). Macular edema and vitreous detachment. Ann Ophthalmol.
  75. Macular holes and macular pucker: the role of vitreoschisis as imaged by optical coherence tomography/scanning laser ophthalmoscopy. Trans Am Ophthalmol Soc. 2007;105:121–129; discussion 129–131.
  76. McCuen BW 2nd. Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs.
  77. (1994). Mechanisms of photo-induced vitreous liquefaction. Curr Eye Res.
  78. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial.
  79. Microplasmin: ex vivo characterization of its activity in porcine vitreous.
  80. Molecular biology of pharmacologic vitreolysis.
  81. (1994). Molecular mechanisms of photochemically induced posterior vitreous detachment. Ophthalmic Res.
  82. (1989). Morphology and ultrastructure of human vitreous fibers. Invest Ophthalmol Vis Sci.
  83. (2001). Optic disc, foveal, and extrafoveal damage due to surgical separation of the vitreous. Arch Ophthalmol.
  84. (2005). Opticin binds to heparan and chondroitin sulfate proteoglycans. Invest Ophthalmol Vis Sci.
  85. Paracentral scotomata: a new finding after vitrectomy for idiopathic macular hole.
  86. Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy.
  87. (2005). Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc.
  88. (1993). Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol.
  89. Pharmacologic vitreodynamics.
  90. Pharmacologic vitreolysis – premise and promise of the first decade.
  91. Pharmacologic vitreolysis combining the two enzymes plasmin and hyaluronidase. Retina. 2005;25(5):674; author reply 674–675.
  92. Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats.
  93. Pharmacologic vitreolysis.
  94. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes.
  95. Plasmin enzyme-assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system.
  96. Plasmin enzymeassisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity.
  97. (2002). Plasmin-assisted vitrectomy eliminates cortical vitreous remnants. Eye (Lond).
  98. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.
  99. Plasminogen in proliferative vitreoretinal disorders.
  100. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
  101. Posterior precortical vitreous pocket.
  102. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study.
  103. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration?
  104. Posterior vitreoschisis. An echographic finding in proliferative diabetic retinopathy.
  105. Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous.
  106. Posterior vitreous detachment induced by microplasmin.
  107. (2006). Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis. Invest Ophthalmol Vis Sci.
  108. Posterior vitreous detachment with dispase.
  109. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol.
  110. Posterior vitreous detachment: evolution and complications of its early stages.
  111. (1985). Posterior vitreous detachment. A combined clinical and physiochemical study. Graefes Arch Clin Exp Ophthalmol.
  112. Prognostic value of vitreous findings in diabetic retinopathy.
  113. PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy.
  114. Recombinant human microplasmin: production and potential therapeutic properties.
  115. Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide.
  116. Risk of iatrogenic peripheral retinal breaks in 20-G pars plana vitrectomy.
  117. Role of laminin in the attachment of PAM 212 (epithelial) cells to basement membrane collagen.
  118. Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion.
  119. Role of the vitreous in central retinal vein occlusion.
  120. (2004). Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest Ophthalmol Vis Sci.
  121. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes.
  122. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
  123. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res.
  124. (1986). Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta. Graefes Arch Clin Exp Ophthalmol.
  125. (1988). Surgical excision of the attached posterior hyaloid. Arch Ophthalmol.
  126. (1988). The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor. Graefes Arch Clin Exp Ophthalmol.
  127. (1997). The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol Scand.
  128. The effects of bacterial collagenase in rabbit vitreous.
  129. The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment.
  130. The gel state of the vitreous and ascorbate-dependent oxygen consumption: relationship to the etiology of nuclear cataracts.
  131. The mechanism of action of hyaluronidase.
  132. The pattern of vitreous syneresis: a study of 800 autopsy eyes. In:
  133. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1.
  134. (2004). The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment. Retina.
  135. The role of the vitreous in diabetic macular edema.
  136. (1990). The safety of intravitreal hyaluronidase. A clinical and histologic study. Invest Ophthalmol Vis Sci.
  137. The vitreous gel: more than meets the eye.
  138. (1989). The vitreous: structure, function, and pathobiology.
  139. Tissue plasminogen activator in the treatment of vitreoretinal diseases.
  140. TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a doublemasked, multicenter trial.
  141. TPA-assisted vitrectomy for proliferative diabetic retinopathy.
  142. Transconjunctival sutureless 23-gauge vitrectomy.
  143. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.
  144. Trempe CL. Role of posterior vitreous detachment in idiopathic macular holes.
  145. Trempe CL. Role of the vitreous in branch retinal vein occlusion.
  146. (1991). Trempe CL. Role of the vitreous in posterior segment neovascularization in central retinal vein occlusion. Ophthalmic Surg.
  147. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema.
  148. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.
  149. Use of autologous plasmin during vitrectomy for diabetic maculopathy.
  150. (1971). Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol.
  151. Vitreomacular adhesion in active and end-stage age-related macular degeneration.
  152. Vitreoretinal alterations following laser in situ keratomileusis: clinical and experimental studies.
  153. Vitreoretinal juncture; topographical variations.
  154. Vitreoretinal juncture. Synchysis senilis and posterior vitreous detachment.
  155. Vitreoretinal morphology of plasmin-treated human eyes.
  156. Vitreoretinal relationship in diabetic retinopathy. A biomicroscopic evaluation.
  157. (2010). Vitreoretinal traction created by conventional cutters during vitrectomy. Ophthalmology.
  158. (2009). Vitreous as a substrate for vitreolysis. Dev Ophthalmol.
  159. (1967). Vitreous traction at the posterior pole of the fundus due to alterations in the vitreous posterior. Trans Am Acad Ophthalmol Otolaryngol.